Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Longevity Health Holdings, Inc.CTCX · Entity 8659 | Director · President and CEO | August 17, 2023 | August 31, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Longevity Health Holdings, Inc.
Report date August 17, 2023 · Filed August 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,750 |
Ending reported balance
After 2023-08-28 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2023-08-17 · Purchase · Acquired 450 · Balance 450 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1. Row 2 · 2023-08-18 · Purchase · Acquired 1,200 · Balance 1,650 F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.65 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2. Row 3 · 2023-08-21 · Purchase · Acquired 300 · Balance 1,950 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.63 to $3.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3. Row 4 · 2023-08-22 · Purchase · Acquired 100 · Balance 2,050 Row 5 · 2023-08-23 · Purchase · Acquired 200 · Balance 2,250 F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.58 to $3.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4. Row 6 · 2023-08-24 · Purchase · Acquired 200 · Balance 2,450 Row 7 · 2023-08-25 · Purchase · Acquired 200 · Balance 2,650 Row 8 · 2023-08-28 · Purchase · Acquired 100 · Balance 2,750 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.65 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.63 to $3.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3.
F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.58 to $3.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2023 Filed Aug 31, 2023 01:52 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | PurchaseCommon Stock | 100 | $3.49 | $349.00 |
DisclosureSEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 8 Hubbell Randolph W · CIK 0001984207 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,750 Read SEC document |
| August 25, 2023 Filed Aug 31, 2023 01:52 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | PurchaseCommon Stock | 200 | $3.50 | $700.00 |
DisclosureSEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 7 Hubbell Randolph W · CIK 0001984207 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,650 Read SEC document |
| August 24, 2023 Filed Aug 31, 2023 01:52 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | PurchaseCommon Stock | 200 | $3.57 | $714.00 |
DisclosureSEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 6 Hubbell Randolph W · CIK 0001984207 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,450 Read SEC document |
| August 23, 2023 Filed Aug 31, 2023 01:52 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | PurchaseCommon Stock | 200 | $3.61 | $721.00 |
DisclosureSEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 5 Hubbell Randolph W · CIK 0001984207 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.58 to $3.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4. Read SEC document |
| August 22, 2023 Filed Aug 31, 2023 01:52 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | PurchaseCommon Stock | 100 | $3.51 | $351.00 |
DisclosureSEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 4 Hubbell Randolph W · CIK 0001984207 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,050 Read SEC document |
| August 21, 2023 Filed Aug 31, 2023 01:52 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | PurchaseCommon Stock | 300 | $3.67 | $1,100.01 |
DisclosureSEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 3 Hubbell Randolph W · CIK 0001984207 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,950 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.63 to $3.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3. Read SEC document |
| August 18, 2023 Filed Aug 31, 2023 01:52 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | PurchaseCommon Stock | 1,200 | $3.74 | $4,482.00 |
DisclosureSEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 2 Hubbell Randolph W · CIK 0001984207 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,650 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.65 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2. Read SEC document |
| August 17, 2023 Filed Aug 31, 2023 01:52 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | PurchaseCommon Stock | 450 | $3.72 | $1,674.00 |
DisclosureSEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 1 Hubbell Randolph W · CIK 0001984207 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:33 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 480,110 | Not disclosed Strike: $2.11 | Not disclosed |
DisclosureSEC source: 0001062993-23-015052 · form4.xml · derivative · entry 3 Hubbell Randolph W · CIK 0001984207 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,110 Underlying: Common Stock · 480,110 shares Expires 2031-09-23 F4 · price: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F3 · derivative.exercise_date: Options to purchase 480,110 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:33 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 37,642 | Not disclosed Strike: $2.27 | Not disclosed |
DisclosureSEC source: 0001062993-23-015052 · form4.xml · derivative · entry 2 Hubbell Randolph W · CIK 0001984207 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,642 Underlying: Common Stock · 37,642 shares Expires 2029-07-19 F4 · price: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F2 · derivative.exercise_date: Options to purchase 37,642 shares of common stock of Legacy Carmell (as defined below) granted on July 19, 2019, which vest as follows: 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022. The remaining 25% will vest and become exercisable on July 19, 2023. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 00:33 UTC | Longevity Health Holdings, Inc. CTCX · Entity 8659 | GrantStock Option (right to buy) · Derivative | 217,175 | Not disclosed Strike: $1.79 | Not disclosed |
DisclosureSEC source: 0001062993-23-015052 · form4.xml · derivative · entry 1 Hubbell Randolph W · CIK 0001984207 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,175 Underlying: Common Stock · 217,175 shares Expires 2027-06-20 F4 · price: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. F1 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.